$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases

Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.